bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

Planet Labs

Investors seeking opportunities among growth stocks could be interested in the following small caps, as they represent companies whose trailing 12-month net income per share has improved significantly on a year-over-year basis.

2 Small Caps for Growth-Focused Investors

Investors, prodded by analysts, warmed up to the company after another FDA-approved therapy.

Why Shares of Bluebird Bio Jumped 15.7% on Tuesday

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

Bluebird Bio Inc (NASDAQ:BLUE) is in the spotlight today, after the U.S. Food and Drug Administration (FDA) approved SKYSONA, its gene therapy for the treatment of Cerebral Adrenoleukodystrophy (CALD) -- a rare neurological disorder found in children's brains ages three to 12.

Bluebird Stock Reverses Gains, Down Nearly 12%

Shares of Bluebird Bio (NASDAQ: BLUE ) were trending higher today in premarket trading on news that the U.S. Food and Drug Administration (FDA) approved the biotechnology company's gene therapy that treats a rare and deadly brain disorder in children. BLUE stock has since dropped lower, down about 9% at the time of writing.

Bluebird Bio (BLUE) Stock Is in Focus Following FDA Approval

The company anticipates the product to be available by the end of 2022.

Bluebird Bio Stock Soars on FDA Approval of Gene Therapy for Rare Neurological Disease

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). The Company also confirmed that the previous clinical hold on the eli-cel clinical development program has been lifted. CALD is a rare, progr

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

Bed Bath & Beyond

Is it worth taking a chance on these stocks?

2 Risky Stocks That Are Running Low on Cash

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that Jason Cole, Chief Strategy and Financial Officer, plans to leave bluebird bio to pursue new career opportunities. Throughout his 8.5 years at bluebird, Mr. Cole has held multiple roles including General Counsel/Chief Legal Officer (2014-2019), Chief Operating & Legal Officer (2019-2021) and Chief Business Officer (2021-2022). Throughout his tenure, Mr. Cole helped guide bluebird's evolution from a sma

Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall

Teladoc

Both are facing significant challenges that might get worse before they get better.

Avoid Buying the Dip With These 2 Stocks During the Nasdaq Bear Market

Axsome Therapeutics

Alnylam Pharmaceuticals

Karuna Therapeutics Inc

Biotech stocks are scorching right now. But the best of the best have strong gains.

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others

Diebold Nixdorf Inc

FuboTV

Transocean

Under Armour

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

These 5 Well-Known Stocks Trade Under $10 and Have Abundant Upside Potential

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

This biotech really needed some good news.

Should You Buy This Growth Stock Following a Major Approval?

bluebird bio has a lot of future potential, but no guarantees. A look at whether the risk outweighs the potential rewards.

bluebird bio: A Speculative Buy With Extraordinary Upside Potential

Analysts were lukewarm on the seemingly very positive news reported by the company midweek.

Why Bluebird Bio's Stock Dived by Over 11% This Week

Source: rafapress / Shutterstock Bluebird Bio (NASDAQ: BLUE ) stock is on the move Thursday following U.S. Food and Drug Administration (FDA) approval for ZYNTEGLO. ZYNTEGLO is a gene therapy designed for patients that require regular red blood cell (RBC) transfusions.

BLUE Stock Moves as FDA Approves Bluebird Bio's Gene Therapy

bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.

bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia

Shares of Buebird Bio Inc. BLUE, +7.90% jumped 12.1% in trading on Wednesday after the Food and Drug Administration approved the company's gene therapy as a treatment for beta‑thalassemia in some adult and pediatric patients. Beta-thalassemia is a rare, genetic blood disease, and the patients who qualify for the treatment require regular red blood cell transfusions.

Bluebird announces FDA approval of gene therapy for rare blood disease

SOMERVILLE, Mass.--(BUSINESS WIRE)--Following the FDA approval of ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions, today bluebird bio released details of its U.S. commercial infrastructure to support rapid access to ZYNTEGLO, including an innovative, outcomes-based contract offering and a comprehensive patient support program. “As the first and only FDA-appro

bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced the U.S. Food and Drug Administration (FDA) has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. “The FDA approval of ZYNTEGLO offers people with beta-thalassemia the possibility of freedom from burdensome

bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.

bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth

Novavax

Investing in biotech stocks without any drugs on the market can be scary. These suggestions can help you make money in this high-risk sector.

News for bluebird bio Stock (BLUE)